CDC

LSU Researchers' Nootkatone Studies Could Lead to Prevention of Lyme Disease

Retrieved on: 
Tuesday, April 9, 2024
Ozone, SCI, Innovation, Lyme disease, Biting, Ant, DEET, Tick, Research, Notifiable disease, Nootkatone, Biology, Che, Military personnel, Leg, NSF, Mosquito net, World Health Organization, CDC, Malaria, WHO, Patent, Chemical engineering, Biol, Tree, West Nile virus, FDA, Defense, Deer, LSU, Vaccine

The LSU researchers propose decreasing the cost of the nootkatone synthesis, making any products made with the compound affordable to the general public.

Key Points: 
  • The LSU researchers propose decreasing the cost of the nootkatone synthesis, making any products made with the compound affordable to the general public.
  • “The family of compounds that make up nootkatone is already proven to be both safer and more effective than existing commercial repellents,” principal investigator Dooley said.
  • Years ago, Laine discovered the efficacy of nootkatone as an insect repellent while collaborating with retired LSU AgCenter Entomologist Gregg Henderson in Laine’s lab.
  • Mosquito nets could be covered with it, or they could have cloth ankle bands with nootkatone so ticks can’t crawl up your leg.

Enhancing Positive Emotions to Prevent Depression in Youth - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, April 2, 2024
Depression, Emotion, Vanderbilt University, Mood, Associate, Risk, Research, Neuroscience, Brain, Psychology, Happiness, CDC, Suicide, Sadness

The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.

Key Points: 
  • The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds will be the webinar host.
  • Register today at BBRFoundation.org
    Treatment for depression traditionally focuses on reducing negative emotions like sadness or anger and less on increasing positive emotions like contentment and happiness.
  • In this talk, Dr. Kujawa will first review research informed by neuroscience that highlights difficulties with positive emotions as a key risk factor for the development of depression in youth.

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Retrieved on: 
Tuesday, April 2, 2024
S. aureus, Risk, Patient, Tissue, Staphylococcus aureus, Infection, CDC, Staphylococcus, Animal, Antigen, Vaccine

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.

Key Points: 
  • In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
  • Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
    There is no S. aureus vaccine available for human use.
  • Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options.
  • The Centers for Disease Control and Prevention (CDC) has reported 120,000 bloodstream infections associated with S. aureus in the US annually.

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Retrieved on: 
Tuesday, April 2, 2024
Health, Advisory Committee, Disease, OMX, Partnership, Risk, Trust, Pharmacy, Public, Mpox, Infection, CDC, Vaccination, Vaccine, FDA, Government, ACIP, Pharmaceutical industry

Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.

Key Points: 
  • Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.
  • According to estimates from the CDC, two (2) million U.S. individuals are eligible for vaccination against mpox4.
  • Recent data shows 60% of this population remains completely unvaccinated, and 15% have received only one dose of the vaccine5.
  • Through its existing nationwide vaccine distribution structure, Bavarian Nordic is now making the mpox vaccine commercially available across the nation.

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

Retrieved on: 
Thursday, March 28, 2024
FSA, U.S. FDA, Arm, Heroin, Risk, Education, Pharmacy, School, Naloxone, Policy, EBS, Flexible, House, Drug, OTC, CDC, Restaurant, Medicaid, National Safety Council, AED, HSA, FDA, Emergent BioSolutions, NSC, Medicine, Fentanyl, Pharmaceutical industry

Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.

Key Points: 
  • Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.
  • Since the OTC launch, NARCAN® Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites.
  • Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.
  • “That’s why we remain committed to increasing awareness of NARCAN® Nasal Spray availability.

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Retrieved on: 
Thursday, March 28, 2024
COCP, MERS, Research, SARS, Enzyme, Drug discovery, Influenza, CFO, COVID-19, Lung, Coronavirus, RNA, Gastroenteritis, G&A, Death, SARS-CoV-2, Trial of the century, IND, Disease, World Health Organization, Post-exposure prophylaxis, Clinical trial, CDC, Safety, Pharmacokinetics, Cocrystal, Therapy, FDA, Pharmaceutical industry

Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.

Key Points: 
  • Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.
  • Cocrystal reported unrestricted cash as of December 31, 2023 of $26.4 million, compared with $37.1 million as of December 31, 2022.
  • Net cash used in operating activities for 2023 was $14.7 million, compared with $21.4 million for 2022.
  • The Company had working capital of $25.0 million and 10.2 million common shares outstanding as of December 31, 2023.

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Retrieved on: 
Wednesday, March 27, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

Key Points: 
  • Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.
  • The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA.

Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Legal, Class Action Lawsuit, Native American, Communications, Professional Services, Social Media, Consumer, Health, Other Professional Services, Snap Inc., Public health, Tribe, Robins Kaplan LLP, Spirit Lake Tribe, Defendant, Meta Platforms, Social media, Behavior informatics, CNN, Female, LLP, Alphabet Inc., Adolescence, Complaint, CDC, ByteDance, Policy, Youth

Today, Robins Kaplan LLP filed a first-of-its-kind lawsuit on behalf of the Spirit Lake Tribe in North Dakota and the Menominee Indian Tribe of Wisconsin against entities that include Facebook and Instagram parent company Meta Platforms, Inc., Snap Inc., TikTok parent company ByteDance, and Alphabet Inc., which owns YouTube and Google.

Key Points: 
  • Today, Robins Kaplan LLP filed a first-of-its-kind lawsuit on behalf of the Spirit Lake Tribe in North Dakota and the Menominee Indian Tribe of Wisconsin against entities that include Facebook and Instagram parent company Meta Platforms, Inc., Snap Inc., TikTok parent company ByteDance, and Alphabet Inc., which owns YouTube and Google.
  • The complaint alleges that rampant social media addiction for Native American teenagers is contributing to suicide rates that are staggeringly higher than their adolescent counterparts.
  • The Center for Native American Youth notes that Tribal teen suicide rates are roughly 3.5 times higher than the national average in the United States.
  • We are demanding these social media corporations take responsibility for intentionally creating dangerous features that ramp up the compulsive use of social media by the youth on our Reservation.”
    The complaint details how U.S.

Estuary Achieves Three Google Cloud Ready Designations

Retrieved on: 
Tuesday, April 9, 2024
Cloud, Google Cloud, Software as a service, Entrepreneurship, SQL, BigQuery, NetSuite, SQL Server, ETL, CDC, MySQL, Network equipment provider

NEW YORK, April 9, 2024 /PRNewswire/ -- Estuary, the only fully managed real-time CDC and streaming ETL platform, announced it has achieved three Google Cloud Ready designations: Google Cloud Ready – BigQuery, Google Cloud Ready – Cloud SQL, and Google Cloud Ready – AlloyDB. Estuary's native CDC connections to SQL Server, MySQL, Postgres, NetSuite and many other sources and targets allow Google Cloud users to replicate data to and from these solutions in real-time. 

Key Points: 
  • Designations validate real-time change data capture (CDC) and streaming ETL for AlloyDB, Cloud SQL, and BigQuery
    NEW YORK, April 9, 2024 /PRNewswire/ -- Estuary, the only fully managed real-time CDC and streaming ETL platform, announced it has achieved three Google Cloud Ready designations: Google Cloud Ready – BigQuery, Google Cloud Ready – Cloud SQL, and Google Cloud Ready – AlloyDB.
  • "Google Cloud has long been a strategic partner for Estuary," said David Yaffe, Co-Founder and CEO of Estuary.
  • Google Cloud's engineering teams validate partner integrations as part of the Google Cloud Ready initiative.
  • Estuary has met or surpassed the core sets of functional requirements in collaboration with Google Cloud's engineering teams, ensuring that it can provide an excellent experience for Google Cloud customers integrating with Google SQL, BigQuery and AlloyDB.

Remission Medical Partners with Sterling Urgent Care to Expand Access to Rheumatology Services

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Arthralgia, Patient, Medicine, Cardiology, Partnership, Rheumatism, PRO, Quality of life, Sterling, LLM, Arthritis, CDC, Region, Work, Human, Hospital

RICHMOND, Va., April 9, 2024 /PRNewswire/ -- Remission Medical announced a partnership with clinical innovator Sterling Urgent Care, to make access to Rheumatology treatment far more convenient across four states: Idaho, Utah, Wyoming and Montana.

Key Points: 
  • Remission Medical is a national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance.
  • According to Sterling Urgent Care spokesperson Dan Kenning, with 21 locations across four states, Sterling goes beyond typical urgent care.
  • They offer advanced primary care in specialties like cardiology, pulmonology, and now rheumatology, prioritizing swift and accurate diagnosis and treatment.
  • Sterling also leads in affordable healthcare with unique membership programs for individuals and businesses, aiming to provide quality care to those without access.